WAVE LIFE SCIENCES LTD. Research and Development Expense
WAVE LIFE SCIENCES LTD. (WVE) reported Research and Development Expense of $51.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. research and development expense for the quarter ending 2026-06-30 was $51.29M, a 18.00% increase year-over-year.
- WAVE LIFE SCIENCES LTD. research and development expense for the quarter ending 2026-03-31 was $47.44M, a 16.78% increase year-over-year.
- WAVE LIFE SCIENCES LTD. research and development expense for the quarter ending 2025-12-31 was $52.81M, a 18.30% increase year-over-year.
- WAVE LIFE SCIENCES LTD. research and development expense for the quarter ending 2025-09-30 was $45.87M, a 11.35% increase year-over-year.
- WAVE LIFE SCIENCES LTD. research and development expense for fiscal 2025 was $182.78M, a 14.46% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. research and development expense for fiscal 2024 was $159.68M, a 22.82% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. research and development expense for fiscal 2023 was $130.01M, a 12.22% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. research and development expense for fiscal 2022 was $115.86M, a 4.94% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.29M 10-Q · filed 2026-07-30 | $98.73M 10-Q · filed 2026-07-30 | $151.55M derived: sum of 3 quarters · filed 2026-07-30 | $197.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $47.44M 10-Q · filed 2026-04-28 | $100.25M derived: sum of 2 quarters · filed 2026-04-28 | $146.13M derived: sum of 3 quarters · filed 2026-04-28 | $189.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $52.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $98.69M derived: sum of 2 quarters · filed 2026-02-26 | $142.16M derived: sum of 3 quarters · filed 2026-07-30 | $182.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $45.87M 10-Q · filed 2025-11-10 | $89.34M derived: sum of 2 quarters · filed 2026-07-30 | $129.97M 10-Q · filed 2025-11-10 | $174.61M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $43.47M 10-Q · filed 2026-07-30 | $84.09M 10-Q · filed 2026-07-30 | $128.74M derived: sum of 3 quarters · filed 2026-07-30 | $169.93M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $40.62M 10-Q · filed 2026-04-28 | $85.27M derived: sum of 2 quarters · filed 2026-04-28 | $126.46M derived: sum of 3 quarters · filed 2026-04-28 | $166.86M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $44.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.84M derived: sum of 2 quarters · filed 2026-02-26 | $126.23M derived: sum of 3 quarters · filed 2026-02-26 | $159.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $41.20M 10-Q · filed 2025-11-10 | $81.59M derived: sum of 2 quarters · filed 2025-11-10 | $115.04M 10-Q · filed 2025-11-10 | $149.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $40.39M 10-Q · filed 2025-07-30 | $73.84M 10-Q · filed 2025-07-30 | $107.91M derived: sum of 3 quarters · filed 2026-02-26 | $139.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $33.45M 10-Q · filed 2025-05-08 | $67.52M derived: sum of 2 quarters · filed 2026-02-26 | $99.16M derived: sum of 3 quarters · filed 2026-02-26 | $132.48M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $34.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $65.72M derived: sum of 2 quarters · filed 2026-02-26 | $99.03M derived: sum of 3 quarters · filed 2026-02-26 | $130.01M 10-K · filed 2026-02-26 |
| 2023-09-30 | $31.64M 10-Q · filed 2024-11-12 | $64.96M derived: sum of 2 quarters · filed 2024-11-12 | $95.94M 10-Q · filed 2024-11-12 | $127.01M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $33.31M 10-Q · filed 2024-08-08 | $64.29M 10-Q · filed 2024-08-08 | $95.37M derived: sum of 3 quarters · filed 2025-03-04 | $122.95M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $30.98M 10-Q · filed 2024-05-10 | $62.06M derived: sum of 2 quarters · filed 2025-03-04 | $89.63M derived: sum of 3 quarters · filed 2025-03-04 | $119.36M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $31.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $58.65M derived: sum of 2 quarters · filed 2025-03-04 | $88.39M derived: sum of 3 quarters · filed 2025-03-04 | $115.86M 10-K · filed 2025-03-04 |
| 2022-09-30 | $27.57M 10-Q · filed 2023-11-09 | $57.31M derived: sum of 2 quarters · filed 2023-11-09 | $84.78M 10-Q · filed 2023-11-09 | $110.54M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $29.73M 10-Q · filed 2023-08-03 | $57.20M 10-Q · filed 2023-08-03 | $82.96M derived: sum of 3 quarters · filed 2023-08-03 | $114.05M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $27.47M 10-Q · filed 2023-05-03 | $53.23M derived: sum of 2 quarters · filed 2023-05-03 | $84.32M derived: sum of 3 quarters · filed 2023-05-03 | $115.95M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $25.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $56.85M derived: sum of 2 quarters · filed 2023-03-23 | $88.48M derived: sum of 3 quarters · filed 2023-03-23 | $121.88M 10-K · filed 2023-03-23 |
| 2021-09-30 | $31.09M 10-Q · filed 2022-11-10 | $62.72M derived: sum of 2 quarters · filed 2022-11-10 | $96.11M 10-Q · filed 2022-11-10 | $126.15M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $31.64M 10-Q · filed 2022-08-11 | $65.03M 10-Q · filed 2022-08-11 | $95.06M derived: sum of 3 quarters · filed 2022-08-11 | $123.34M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $33.39M 10-Q · filed 2022-05-12 | $63.43M derived: sum of 2 quarters · filed 2022-05-12 | $91.70M derived: sum of 3 quarters · filed 2022-05-12 | $123.18M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $30.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $58.31M derived: sum of 2 quarters · filed 2022-03-03 | $89.79M derived: sum of 3 quarters · filed 2022-03-03 | $130.94M 10-K · filed 2022-03-03 |
| 2020-09-30 | $28.27M 10-Q · filed 2021-11-10 | $59.75M derived: sum of 2 quarters · filed 2021-11-10 | $100.91M 10-Q · filed 2021-11-10 | $150.04M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $31.48M 10-Q · filed 2021-08-05 | $72.64M 10-Q · filed 2021-08-05 | $121.76M derived: sum of 3 quarters · filed 2021-08-05 | $166.35M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $41.16M 10-Q · filed 2021-05-13 | $90.29M derived: sum of 2 quarters · filed 2021-05-13 | $134.87M derived: sum of 3 quarters · filed 2021-05-13 | $176.48M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $49.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $93.71M derived: sum of 2 quarters · filed 2021-03-04 | $135.32M derived: sum of 3 quarters · filed 2021-03-04 | $175.43M 10-K · filed 2021-03-04 |
| 2019-09-30 | $44.59M 10-Q · filed 2020-11-09 | $86.19M derived: sum of 2 quarters · filed 2020-11-09 | $126.30M 10-Q · filed 2020-11-09 | $166.11M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $41.60M 10-Q · filed 2020-08-10 | $81.72M 10-Q · filed 2020-08-10 | $121.53M derived: sum of 3 quarters · filed 2020-08-10 | $154.40M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $40.11M 10-Q · filed 2020-05-11 | $79.92M derived: sum of 2 quarters · filed 2020-05-11 | $112.80M derived: sum of 3 quarters · filed 2020-05-11 | $145.34M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $39.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $72.69M derived: sum of 2 quarters · filed 2020-03-02 | $105.23M derived: sum of 3 quarters · filed 2020-03-02 | $134.43M 10-K · filed 2020-03-02 |
| 2018-09-30 | $32.88M 10-Q · filed 2019-11-05 | $65.42M derived: sum of 2 quarters · filed 2019-11-05 | $94.62M 10-Q · filed 2019-11-05 | $119.99M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $32.55M 10-Q · filed 2019-08-06 | $61.74M 10-Q · filed 2019-08-06 | $87.11M derived: sum of 3 quarters · filed 2020-03-02 | $107.21M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $29.20M 10-Q · filed 2019-05-10 | $54.56M derived: sum of 2 quarters · filed 2020-03-02 | $74.66M derived: sum of 3 quarters · filed 2020-03-02 | $93.77M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $25.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $45.47M derived: sum of 2 quarters · filed 2020-03-02 | $64.57M derived: sum of 3 quarters · filed 2020-03-02 | $79.31M 10-K · filed 2020-03-02 |
| 2017-09-30 | $20.10M 10-Q · filed 2018-11-09 | $39.20M derived: sum of 2 quarters · filed 2018-11-09 | $53.94M 10-Q · filed 2018-11-09 | $67.94M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $19.10M 10-Q · filed 2018-08-09 | $33.84M 10-Q · filed 2018-08-09 | $47.84M derived: sum of 3 quarters · filed 2019-03-01 | $61.52M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $14.74M 10-Q · filed 2018-05-09 | $28.73M derived: sum of 2 quarters · filed 2019-03-01 | $42.42M derived: sum of 3 quarters · filed 2019-03-01 | $50.82M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $13.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $27.68M derived: sum of 2 quarters · filed 2019-03-01 | $36.08M derived: sum of 3 quarters · filed 2019-03-01 | $40.82M 10-K · filed 2019-03-01 |
| 2016-09-30 | $13.69M 10-Q · filed 2017-11-09 | $22.09M derived: sum of 2 quarters · filed 2017-11-09 | $26.82M 10-Q · filed 2017-11-09 | $30.29M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $8.40M 10-Q · filed 2017-08-09 | $13.14M 10-Q · filed 2017-08-09 | $16.61M derived: sum of 3 quarters · filed 2018-03-12 | $18.74M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $4.74M 10-Q · filed 2017-05-10 | $8.20M derived: sum of 2 quarters · filed 2018-03-12 | $10.34M derived: sum of 3 quarters · filed 2018-03-12 | $12.19M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $5.60M derived: sum of 2 quarters · filed 2018-03-12 | $7.45M derived: sum of 3 quarters · filed 2018-03-12 | $9.06M 10-K · filed 2018-03-12 |
| 2015-09-30 | $2.13M 10-Q · filed 2016-11-09 | $3.98M derived: sum of 2 quarters · filed 2016-11-09 | $5.59M 10-Q · filed 2016-11-09 | $6.31M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $1.85M 10-Q · filed 2016-08-15 | $3.46M 10-Q · filed 2016-08-15 | $4.18M derived: sum of 3 quarters · filed 2017-03-16 | $4.76M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $1.61M 10-Q · filed 2016-05-16 | $2.33M derived: sum of 2 quarters · filed 2017-03-16 | $2.92M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2014-12-31 | $723.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.31M derived: sum of 2 quarters · filed 2017-03-16 | $2.40M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $585.00K 10-Q · filed 2015-12-17 | $1.67M 10-Q · filed 2015-12-17 | ||
| 2013-12-31 | $1.92M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |